Lauren Karenbauer
Medical · Philadelphia, PANPI 1740060003
Payments from drug & device makers
Across 150 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$310
- Tempus AI, Inc$310
- Novartis$292
- Daiichi Sankyo Inc.$249
- Johnson & Johnson$231
- Incyte Corporation$222
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,401100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $310 |
| Tempus AI, Inc | 7 | $310 |
| Novartis | 14 | $292 |
| Daiichi Sankyo Inc. | 14 | $249 |
| Johnson & Johnson | 9 | $231 |
| Incyte Corporation | 13 | $222 |
| Merck | 7 | $171 |
| AbbVie | 5 | $145 |
| Astellas Pharma US Inc | 7 | $143 |
| Bayer | 6 | $142 |
| Genentech USA, Inc. | 6 | $137 |
| Bristol Myers Squibb | 5 | $116 |
| Sanofi | 3 | $94 |
| Eisai Inc. | 4 | $90 |
| Puma Biotechnology, Inc. | 3 | $70 |
| AVEO Pharmaceuticals, Inc. | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $51 |
| Beigene USA, Inc. | 2 | $51 |
| Pharmacosmos Therapeutics Inc. | 2 | $46 |
| Pharmaessentia USA Corporation | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Genmab U.S., Inc. | 2 | $40 |
| Pfizer | 2 | $36 |
| Array Biopharma Inc | 2 | $34 |
| Celltrion USA Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Immunocore Limited | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $24 |
| Gilead | 1 | $23 |
| Sobi, Inc | 1 | $22 |
| Novocure Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XT CDX$111
How this compares
$3,401 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $6,37711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Philadelphia
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Sarah SmithPhiladelphia$65K
- Victoria WongPhiladelphia$51K
- Parth PatelPhiladelphia$46K
- Zachary LutzPhiladelphia$30K
- Hawah MusaPhiladelphia$13K
- Carl BlackPhiladelphia$13K
- Ashley BarratPhiladelphia$12K
- Jacqueline KernaghanSpringfield$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.